Gritstone Oncology Inc. Stock News

Catalysts for the stocks are just ahead.

Catalysts for the stocks are just ahead.

Gritstone bio Inc. (NASDAQ:GRTS) price on Friday, November 19, rose 0.18% above its previous days close as an upside momentum from buyers pushed the stocks value to $11.18. A look at the stocks price movement, the close in the last trading session was $11.16, moving within a range at $11.00 and $11.48. The beta value Thinking Of Buying Gritstone bio Inc. (NASDAQ: GRTS) Stock? Heres What You Need To Know Read More »

In the last trading session, 1.28 million Gritstone bio Inc. (NASDAQ:GRTS) shares changed hands as the companys beta touched 0. With the companys per share price at $10.87 changed hands at -$0.37 or -3.29% during last session, the market valuation stood at $736.44M. GRTSs last price was a discount, traded about -223.83% off its 52-week Why Gritstone bio Inc. (NASDAQ: GRTS) Stock Shouldnt Be Sold In 2021 Read More »

Gritstone Poised To Dominate mRNA Market

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 18.18% and -12.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock

EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunot

The company uses mRNA technology -- with a new twist.

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immuno

GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants

Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterolog

EMERYVILLE, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) --  Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunothera

Webcast today, September 17 at 1:30pm ET

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapi

They're leaders in therapeutic areas with massive growth potential.